At a glance
ClinicalIndex Comparison RecordN/ACompleted· 43 enrolled
Drug / intervention
Ivabradine +1 moredrug
Likely dose
Ivabradine 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease
In Brief
A clinical study evaluating Ivabradine and Placebo for Coronary Artery Disease. Completed, enrolled 43 participants across 1 site.
Detailed Summary
The purpose of this study in patients with chronic stable coronary artery disease treatable by percutaneous coronary intervention (PCI) is to evaluate the long-term efficacy and safety of the orally taken selective I(f)-inhibitor Ivabradine (Procoralan®, Servier Switzerland) with regard to the promotion of collateral growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesSwitzerland
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedDec 2009
Primary CompletionMar 2013
TodayJul 2026
First PostedDec 25, 2009
Enrollment StartOct 1, 2009
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 16.5 years ago
Interventions
Ivabradinedrug
bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
Placebodrug
bid placebo